Too a lot of my Twitter interactions with biotech-loving retail buyers are disagreeable. If I write an article elevating doubts a couple of small drugmaker’s scientific trial outcomes, or if I name out deceptive statements made by a very promotional biotech CEO, the responses I obtain from individuals who personal the inventory usually run the gamut from “f—okay you, you clueless a–gap” to “I hope you get most cancers and die.”
And typically, the replies to my work get actually nasty.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
